Investors keep piling into biotech stocks and British companies have been reaping the benefits this week.
Exceptionally large amounts of money are continuing to flow through the biotech sector and this week has seen a number of UK companies dive in to tap investors for cash.
Two of the more established players, Autolus Therapeutics plc and Mereo BioPharma Group plc, have taken advantage of their listings on the NASDAQ to boost their coffers with follow-on offerings
Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.
HTX-001 targeting the long non-coding RNA known as Wisper is being developed for non-obstructive hypertrophic cardiomyopathy. HAYA partnered with Lilly last year in obesity.
Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’
The sector is continuing to show resilience despite financial and market challenges.
